Journal of Critical Care
Volume 23, Issue 1 , Pages 11-17, March 2008

The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients

  • Marie-Soleil Delisle

      Affiliations

    • Hôpital de l'Enfant-Jésus, Québec, Québec, Canada
  • ,
  • David R. Williamson

      Affiliations

    • Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
    • Université de Montréal, Montréal, Québec, Canada
  • ,
  • Marc M. Perreault

      Affiliations

    • Université de Montréal, Montréal, Québec, Canada
    • Centre Universitaire de Santé McGill, Montréal, Québec, Canada
  • ,
  • Martin Albert

      Affiliations

    • Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
    • Université de Montréal, Montréal, Québec, Canada
  • ,
  • Xuran Jiang

      Affiliations

    • Queens University, Kingston, Ontario, Canada
  • ,
  • Daren K. Heyland

      Affiliations

    • Queens University, Kingston, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +613 549 6666x3339, fax: +1 613 548 1351.

Abstract 

Purpose

Clinical uncertainty exists regarding the significance of colonization confined to respiratory tract secretions with Candida sp in critically ill patients. Our objectives were to describe such colonization, its associated risk factors, and to examine the clinical outcomes in patients with a clinical suspicion of ventilator-associated pneumonia with isolated Candida colonization compared to those without.

Materials and Methods

In a retrospective analysis of the Canadian ventilator-associated pneumonia study, patients were divided into 2 groups according to the isolated presence or absence of Candida in the respiratory tract enrollment culture. We compared length of mechanical ventilation, intensive care unit and hospital stay, and mortality outcomes between groups. We used multiple logistic regression analysis to determine factors independently associated with Candida colonization and hospital mortality.

Results

Of the 639 eligible patients, 114 (17.8%) were colonized with Candida in the enrollment culture. A multivariate analysis identified female sex (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.02-2.65), number of comorbidities (OR, 1.35; 95% CI, 1.08-1.71), worsening or persistent infiltrate at randomization (OR, 1.92; 95% CI, 1.09-1.38), antibiotics started within 3 days of randomization (OR, 3.16; 95% CI, 1.71-5.83), and on antibiotics at randomization but all started more than 3 days before randomization (OR, 3.04; 95% CI, 1.68-5.50) as variables associated with Candida respiratory tract colonization. A significant increase in median hospital stay (59.9 vs 38.6 days, P = .006) and hospital mortality (34.2% vs 21.0%, P = .003) was observed in patients with Candida colonization. In a multivariate model, Candida colonization of the respiratory tract was independently associated with hospital mortality (OR, 2.47; 95% CI, 1.39-4.37).

Conclusion

Respiratory tract Candida colonization is associated with worse clinical outcomes and is independently associated with increased hospital mortality. However, it is unclear whether Candida colonization is causally related to poor outcomes or whether it is a marker for increased morbidity and mortality.

Keywords: Candida, colonization, Candida airway colonization, Pneumonia, Ventilator-associated pneumonia, Critical care

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by grants from the Canadian Institutes of Health Research and Physicians' Services Incorporated of Ontario, and by unrestricted grants from AstraZeneca, Bayer, and Merck Frosst.

PII: S0883-9441(08)00019-1

doi:10.1016/j.jcrc.2008.01.005

Journal of Critical Care
Volume 23, Issue 1 , Pages 11-17, March 2008